Omnicom Group Inc. vs Revolution Medicines Inc. Common Stock — how do they compare? Omnicom Group Inc. trades at $76.35 (market cap $20.54B), while Revolution Medicines Inc. Common Stock trades at $188.5 (market cap $43.07B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 2.1× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays a 4.27% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| OMC | RVMD | |
|---|---|---|
Market Cap | $20.54B | $43.07B |
Volume | 1,803,209 | 1,184,841 |
Sector | Media | Health |
52-Week High | $88.94 | $221.15 |
52-Week Low | $67.27 | $47.50 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $28.62B | $39.77B |
Dividend Yield | 4.27% | — |
Signals from Pluang's Aura AI — not financial advice
OMC trades at $76.45, up 1.8% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, though 2026 projections show a return to profitability. Recent news highlights leadership in digital marketing and significant new business wins, including $3.3 billion in H1 2026 billings.
The stock presents a value opportunity with a low P/S of 0.84 and a consensus price target of $104.67, implying 37% upside. However, high P/E of 202.35, recent net loss, and advertising market volatility pose risks. Analyst sentiment is cautious with 59% hold ratings, reflecting balanced near-term prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →